Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

WHO Maintains That 2B Worldwide Could Get H1N1
The WHO on Tuesday maintained that roughly two billion people could become infected with the H1N1 (swine flu) virus, Reuters reports. "By the end of a pandemic, anywhere between 15-45 percent of a population will have been infected by the new pandemic virus," WHO spokeswoman Aphaluck Bhatiasevi said, adding that 30 percent, or 2 billion people worldwide, is the mid point of that estimate. "But the estimate comes with a big health warning: no one knows how many people so far have caught the new strain ... and the final number will never be known as many cases are so mild they may go unnoticed," the news service writes (Lynn, 8/4).

Jumping Genes Discovery "Challenges Current Assumptions"
Jumping genes do most of their jumping, not during the development of sperm and egg cells, but during the development of the embryo itself. The research, published this month in Genes and Development, "challenges standard assumptions on the timing of when mobile DNA, so-called jumping genes, insert into the human genome," says senior author Haig H. Kazazian Jr., MD, Seymour Gray Professor of Molecular Medicine in Genetics at the University of Pennsylvania School of Medicine.
News of the day
Outstanding Canadians Tireless In Their Efforts To Help Those Living With Dementia
This June, the Alzheimer Society is recognizing the extraordinary efforts of four Canadians who are rising to the challenge in the fight against Alzheimer"s disease and related dementias.
Diagnostics

Merck Seeks European License For Cladribine for relapsing remitting MS

Merck Serono announced that it is seeking a European license for cladribine, its oral therapy that is in late-stage clinical trials for relapsing remitting MS. The announcement comes after results of a phase III clinical trial were reported in April at the annual American Academy of Neurology meeting in Seattle Washington. If the application meets all of the regulatory hurdles, it is set to be the first oral disease modifying drug available to people with MS. If no delays are made, cladribine could be available as early as the middle of 2010, which could mean more choice for people with MS. Multiple Scleroris Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009